CRO Velesco Pharma adds compound management services

By Melissa Fassbender

- Last updated on GMT

(Image: iStock)
(Image: iStock)

Related tags Laboratory Pharmacology Labrador retriever

The contract research organization (CRO) Velesco Pharma has opened a new laboratory in its Plymouth, MI-based facility to support an increased demand for materials management.

Velesco Pharma's new non-GMP materials handling lab creates and enhances our capabilities to store, dispense, manage inventory and distribute materials such as API, intermediates and compounds transitioning into development​,” Gerry Cox, M.S. CPA, Chief Operating Officer at Velesco told

Cox explained that the company has observed an upturn in the demand for the storage and management of early phase materials in both its non-GMP and GMP operations.

“Our increased capacity has led to an increased focus on meeting this demand​,” he added.

The new capacity complements the company’s current cGMP material storage and dispensing operation in Kalamazoo, MI. However, the new labs adds compound management services for materials with either cGMP or non-GMP requirements. Services include long- and short-term storage of materials at ambient, refrigerated or frozen temperatures, in addition to labeling and distribution.

We have observed demand for these services from smaller pharmaceutical and biotech companies​,” said Cox. “These organizations are actively involved in moving new compounds through the development process but do not have the in-house capabilities to meet their material management needs​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers